In silico discovery and biological validation of ligands of FAD synthase, a promising new antimicrobial target
Resumen: New treatments for diseases caused by antimicrobial-resistant microorganisms can be developed by identifying unexplored therapeutic targets and by designing efficient drug screening protocols. In this study, we have screened a library of compounds to find ligands for the flavin-adenine dinucleotide synthase (FADS) -a potential target for drug design against tuberculosis and pneumonia- by implementing a new and efficient virtual screening protocol. The protocol has been developed for the in silico search of ligands of unexplored therapeutic targets, for which limited information about ligands or ligand-receptor structures is available. It implements an integrative funnel-like strategy with filtering layers that increase in computational accuracy. The protocol starts with a pharmacophore-based virtual screening strategy that uses ligand-free receptor conformations from molecular dynamics (MD) simulations. Then, it performs a molecular docking stage using several docking programs and an exponential consensus ranking strategy. The last filter, samples the conformations of compounds bound to the target using MD simulations. The MD conformations are scored using several traditional scoring functions in combination with a newly-proposed score that takes into account the fluctuations of the molecule with a Morse-based potential. The protocol was optimized and validated using a compound library with known ligands of the Corynebacterium ammoniagenes FADS. Then, it was used to find new FADS ligands from a compound library of 14, 000 molecules. A small set of 17 in silico filtered molecules were tested experimentally. We identified five inhibitors of the activity of the flavin adenylyl transferase module of the FADS, and some of them were able to inhibit growth of three bacterial species: C. ammoniagenes, Mycobacterium tuberculosis, and Streptococcus pneumoniae, where the last two are human pathogens. Overall, the results show that the integrative VS protocol is a cost-effective solution for the discovery of ligands of unexplored therapeutic targets.
Idioma: Inglés
DOI: 10.1371/journal.pcbi.1007898
Año: 2020
Publicado en: PLoS computational biology 16, 8 (2020), e1007898 1-24
ISSN: 1553-734X

Factor impacto JCR: 4.475 (2020)
Categ. JCR: MATHEMATICAL & COMPUTATIONAL BIOLOGY rank: 8 / 58 = 0.138 (2020) - Q1 - T1
Categ. JCR: BIOCHEMICAL RESEARCH METHODS rank: 16 / 77 = 0.208 (2020) - Q1 - T1

Factor impacto SCIMAGO: 2.628 - Cellular and Molecular Neuroscience (Q1) - Computational Theory and Mathematics (Q1) - Ecology (Q1) - Molecular Biology (Q1) - Genetics (Q1) - Modeling and Simulation (Q1) - Ecology, Evolution, Behavior and Systematics (Q1)

Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)


Creative Commons Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.


Exportado de SIDERAL (2021-09-02-09:37:01)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Artículos



 Registro creado el 2020-09-25, última modificación el 2021-09-02


Versión publicada:
 PDF
Valore este documento:

Rate this document:
1
2
3
 
(Sin ninguna reseña)